Single Group Assignment for Solid Tumors
This trial is designed to study the effect of the drug tipifarnib on the heart's electrical activity following a single 900 mg dose and after repeated 600 mg doses given twice a day. The trial will also assess the safety and pharmacokinetics of tipifarnib.
- Advanced Solid Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom undefined Phase 3 trial • 144 Patients • NCT00093470
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has this treatment undergone the requisite governmental approval processes?
"As this medical trial is in its opening stages, the safety profile of this treatment has only been minimally evaluated and thus receives a score of 1."
How many individuals have been inducted into this experiment?
"Indeed, clinicaltrials.gov reports that this trial is presently recruiting participants. It was originally posted on May 6th 2021 and last updated on August 19th 2022; the research requires recruitment of 20 patients over 3 different sites."
Is this investigation still accessible to participants?
"Affirmative, the information on clinicaltrials.gov reveals that this investigation is still recruiting participants. The experiment was initially advertised on May 6th 2021 and its listing was revised as recently as August 19th 2022. In total, 20 individuals are needed from 3 sites for this trial to proceed."
Has this treatment been tested in any other research studies?
"This treatment made its clinical debut at the Marshfield Medical Center in 2017, with 48 studies done since. Currently, six trials are actively underway - many of them based out of San Antonio, Texas."